Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2016 - 2025)

Neurocrine Biosciences' Asset Utilization Ratio history spans 15 years, with the latest figure at 0.64 for Q4 2025.

  • For Q4 2025, Asset Utilization Ratio fell 0.98% year-over-year to 0.64; the TTM value through Dec 2025 reached 0.64, down 0.98%, while the annual FY2025 figure was 0.69, 1.38% up from the prior year.
  • Asset Utilization Ratio reached 0.64 in Q4 2025 per NBIX's latest filing, down from 0.66 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.67 in Q2 2023 to a low of 0.3 in Q2 2022.
  • Average Asset Utilization Ratio over 5 years is 0.56, with a median of 0.6 recorded in 2024.
  • Peak YoY movement for Asset Utilization Ratio: tumbled 44.95% in 2022, then skyrocketed 125.2% in 2023.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.4 in 2021, then increased by 25.74% to 0.5 in 2022, then grew by 23.48% to 0.62 in 2023, then grew by 4.95% to 0.65 in 2024, then decreased by 0.98% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Asset Utilization Ratio are 0.64 (Q4 2025), 0.66 (Q3 2025), and 0.66 (Q2 2025).